|Bid||10,526.00 x 0|
|Ask||10,524.00 x 0|
|Day's range||10,308.00 - 10,578.00|
|52-week range||7,870.00 - 11,000.00|
|Beta (5Y monthly)||0.17|
|PE ratio (TTM)||130.68|
|Forward dividend & yield||2.10 (2.04%)|
|Ex-dividend date||24 Feb 2022|
|1y target est||N/A|
FDA grants emergency approval to Pfizer's COVID-19 vaccine for use in children 5- to 11-year old and approves Lilly's (LLY) novel diabetes treatment, Mounjaro (tirzepatide).
Strong sales of key products like Keytruda and Gardasil, a significant contribution from Lagevrio and positive pipeline/regulatory developments have been keeping Merck's (MRK) stock afloat in 2022.
AstraZeneca (AZN) partners with a U.K.-based biotech company to develop monoclonal antibodies targeting the COVID-causing virus.